Abiopharma

🔍 Vandekop Amy O'Leary (Executive)

Company: Kalaris Therapeutics, Inc. (KLRS)

Report Date: 2026-08-27

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Stock Option (Right to Buy) at $4.1 per share (Derivative)
  Date: 2026-08-27 | Code: A | Expires: 2036-08-26 | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.